Skip to content
Screener

Maze Therapeutics MAZE Q4 2025 Annual earnings

Reported March 25, 2026 · Before market open

EPS-$0.65Beat by $0.08
Revenue estimate$375.0K
EPS estimate-$0.73

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$333.3K
EPS estimate-$0.79

Financials

Q4 2025

Income statement

See full
Operating income-$38.1M—
Net income-$34.6M—
EPS (diluted)-$0.60-103%

Balance sheet

See full
Cash & equivalents$189.2M-3.8%
Total debt$23.3M-12.5%
Total equity$355.0M+214%
Total assets$397.1M+65.1%

Cash flow

See full
Operating cash flow-$27.7M—
CapEx$34.0K-94.4%
Free cash flow-$27.8M—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.99B—
Enterprise value$1.83B—

Returns & leverage

See full
Debt / equity0.1×—
Current ratio15.5×+5.7×

Segments

By geography

See full
US-—

FAQ

When did Maze Therapeutics report Q4 2025 earnings?
Maze Therapeutics (MAZE) reported Q4 2025 earnings on March 25, 2026 before market open.
What were Maze Therapeutics's Q4 2025 revenue and EPS?
Maze Therapeutics reported eps of $-0.65 for Q4 2025.
Did Maze Therapeutics beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.73 by $0.08.
How did Maze Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 96.5% from $-18.32.
Where can I find Maze Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-122774) and the 10-K periodic report (0001193125-26-122778) directly on SEC EDGAR. The filing index links above go to sec.gov.